ClinicalTrials.gg
Not yet recruitingNCT07949760Updated Nov 19, 2026

WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial

A Phase 2 interventional study of pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine and Computed Tomography in Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma and Metastatic Hormone Receptor-Negative Breast Carcinoma, sponsored by University of Washington. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Washington · Phase 2, Interventional, and Prevention

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies in Breast Neoplasms by University of Washington — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Washington.

Planned enrollment
15th of 56
52 · median 35
Started
2026
with 2 others
Phase 2
23 of 64
5 open now
Primary completion
2030-12
later than 10 of 10 live
Registered
64th of 64
by date

Among the 64 studies in Breast Neoplasms by University of Washington, this one is the 15th largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 10 of the 10 other live ones, and was the 64th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 64 studies in Breast Neoplasms by University of Washington are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by University of Washington, or all of them as a file.
02

Study summary

This phase II trial tests how well the WOKVAC vaccine works in preventing brain metastases in patients with HER2 positive, hormone receptor negative or low breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). WOKVAC is a vaccine made from tumor-associated proteins, pUMVC3, IGFBP2, HER2, and IGF1R, and may help the body build an effective immune response to kill tumor cells. Sargramostim is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets It is a cytokine that is a type of hematopoietic (blood forming) agent. Giving WOKVAC mixed with sargramostim may help prevent the development of brain metastases in patients with HER2 positive, hormone receptor negative or metastatic breast cancer.

Read the detailed description

OUTLINE:

Patients receive WOKVAC mixed with sargramostim intradermally (ID) at months 1, 2, 3, 6, 12, and 24 in the absence of brain metastases or unacceptable toxicity. Patients may also receive tetanus-diptheria immunization with first vaccine per standard of care. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) at baseline and possibly at later study milestones.

After completion of study treatment, patients are followed every 3 months for up to 5 years from the first vaccine.

03

Conditions studied

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Positive Breast Carcinoma
  • Metastatic Hormone Receptor-Negative Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least ≥ 18 years of age
  • confirmed -positive on tumor tissue by immunohistochemistry (IHC) or by fluorescence in situ hybridization (FISH), in accordance with American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for HER2 testing
  • Hormone receptor negative/low on metastatic tumor tissue, if available (primary tumor tissue can be used if metastatic tissue cannot be obtained)

    • Estrogen receptor (ER): ≤ 10 % positive tumor cell nuclei and/or
    • Progesterone receptor (PR): ≤ 10% positive tumor cell nuclei
  • Diagnosed with metastatic disease no more than 24 months prior to enrollment
  • No evidence of on contrast-enhanced MRI within 60 days prior to first vaccine
  • Receiving first- or standard systemic therapy for metastatic disease. Induction + maintenance regimens (e.g., docetaxel + trastuzumab and pertuzumab [HP] followed by HP alone may be counted together as first line)
  • Clinically and radiographically stable disease on most recent restaging, performed ≤ 90 days prior to consent
  • (ECOG) performance status 0 or 1
  • White blood cell ≥ 2.0 THOU/uL (prior to first vaccine)
  • Lymphocyte count ≥ 0.5 THOU/uL (prior to first vaccine)
  • ≥ 0.7 THOU/uL (prior to first vaccine)
  • ≥ 75 THOU/uL (prior to first vaccine)
  • Total ≤ 1.5 x institutional , except participants with Gilbert's syndrome in whom total bilirubin must be \< 3.0 mg/d (prior to first vaccine)
  • (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (prior to first vaccine)
  • Creatinine ≤ 2.0 mg/dL or > 30 mL/min (prior to first vaccine)
  • At least 30 days post systemic prior to first vaccine, unless used as part of prophylaxis to prevent intravenous (IV) contrast reactions.

    • Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed
  • Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment

Exclusion criteria

Exclusion Criteria:

  • Known or suspected CNS disease
  • Prior -targeted vaccine therapy or participation in another HER2-targeted vaccine trial
  • Active uncontrolled intercurrent illness or infection
  • Pregnancy or breastfeeding
  • Current anticancer therapy
  • Major surgery within 4 weeks prior to first vaccination
  • Known to WOKVAC and/or vaccine adjuvant components
  • Uncontrolled or significant cardiac disease, including symptomatic restrictive or dilated cardiomyopathy, unstable angina within 4 months, (NYHA) class III-IV heart failure on active treatment, or symptomatic pericardial effusion
  • Inability to comply with protocol-specified timing restrictions for non-study vaccinations (i.e., administration within 14 days before or after WOKVAC dosing)
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Treatment (WOKVAC, sargramostim)

    Patients receive WOKVAC mixed with sargramostim ID at months 1, 2, 3, 6, 12, and 24 in the absence of brain metastases or unacceptable toxicity. Patients may also receive tetanus-diptheria immunization with first vaccine per standard of care. Additionally, patients undergo blood sample collection and magnetic resonance imaging (MRI) or computed tomography (CT) at baseline and possibly at later study milestones.

    Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Biological: Sargramostim · Biological: Tetanus and Diphtheria Toxoids Adsorbed · Procedure: Biospecimen Collection

Interventions

  • BiologicalpUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine

    Given ID

    Also known as: WOKVAC Vaccine, WOKVAC, pUMVC3-IGFBP2-HER2-IGF1R, pUMVC3-IGFBP2-HER2-IGF1R Vaccine

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • BiologicalSargramostim

    Given ID

    Also known as: 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin

  • BiologicalTetanus and Diphtheria Toxoids Adsorbed

    Given tetanus-diptheria immunization

    Also known as: DECAVAC, Td, Tetanus and Diphtheria Toxoids Adsorbed for Adult Use

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

06

What researchers measure

Primary outcomes

  1. Incidence of brain metastasis

    Will be estimated using the Aalen-Johansen estimator, with death before brain metastasis treated as a competing event. The 5-year cumulative incidence estimate and corresponding 95% confidence interval will be reported.

    Time frame: From the date of first vaccination to the first clinically detected, radiographically confirmed brain metastasis, assessed up to 5 years

Secondary outcomes

  1. Change in interferon gamma

    Will be evaluated using Enzyme-linked Immunosorbent Spot Assay (ELISPOT) on peripheral blood mononuclear cells in response to HER2, IGF1R and IGFBP2 peptide pools. Descriptive summaries will be used for each blood draw, longitudinal modeling (e.g., mixed-effects models) over the course of treatment.

    Time frame: From baseline to post-vaccination timepoints, assessed up to 5 years

  2. Cytotoxic T-cell response

    Responses will be assessed by granzyme B ELISPOT using overlapping peptide pools of the WOKVAC antigens.

    Time frame: From baseline to post-vaccination. assessed up to 5 years

  3. Epitope spreading

    Will be assessed by antibody arrays evaluating the pre-vaccine sera antibody repertoire versus the post-vaccine antibody repertoire.

    Time frame: At 1 month after vaccine #3 and after 3 months at vaccine #4

07

Study locations

1 site
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
    • Cancer Vaccine Institute Clinical Trials Intake · Contactcvitrial@uw.edu · 866-932-8588
    • Natasha Hunter, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2030, 49 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 49 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949760
Collaborators
Ronald Fedler Foundation
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Nov 19, 2026

Study contacts

Cancer Vaccine Institute Clinical Trials Intake
Contact
cvitrial@uw.edu
1-866-932-8588
Natasha Hunter, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion